Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Cardiomyopathy

Cardiomyopathy

Subtypes of Cardiomyopathy

Hypertrophic Cardiomyopathy 9 Dilated Cardiomyopathy 7 Myocarditis 7 Transthyretin cardiomyopathy 5 Atrial Cardiomyopathy 2 Hypertrophic obstructive cardiomyopathy 2 Chagas cardiomyopathy 1 Diabetic cardiomyopathy 1 DMD-associated cardiomyopathy 1 Non-Ischemic Cardiomyopathy 1 Takotsubo syndrome 1 Titin Cardiomyopathy 1 Arrhythmogenic cardiomyopathy 0

37 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Cardiomyopathy

36 trials tracked for Cardiomyopathy: 6 in phase 3 or 4 and 2 with published results. The most-cited published study has 17 citations.

36Trials tracked
6Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 3 Phase 3 3 Phase 2 8 Phase 1 2 Other / NA 20
  1. Phase 3 Implantable Cardioverter-Defibrillator Use in the VA System Completed · 17 cited
  2. Phase 3 Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy Completed · 2 cited
  3. Phase 4 Ranolazine in Ischemic Cardiomyopathy Completed
  4. Phase 4 Can Vitamin D Reduce Heart Muscle Damage After Bypass Surgery? Completed
  5. Phase 4 Statin Therapy for Ischemic and Nonischemic Cardiomyopathy Completed
  6. Phase 3 Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing Completed
Show 30 more trials
  1. Phase 2 Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim2) Completed
  2. Phase 2 Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Diastolic Cardiomyopathy (Aim3) Completed
  3. Phase 2 The Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in Patients Undergoing LVAD Implantation Completed
  4. Phase 2 Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients Completed
  5. Phase 2 Cardiac Hormone Replacement With Brain Natriuretic Peptide (BNP) in Heart Failure Completed
  6. Phase 2 HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne) Completed
  7. Phase 2 The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy Completed
  8. Phase 2 Phase I/II Study of EP-guided Noninvasive Cardiac Radioablation for Treatment of Ventricular Tachycardia Completed
  9. Phase 1 Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab Completed
  10. Phase 1 The Impact of Zinc Supplementation on Left Ventricular Function in Nonischemic Cardiomyopathy Completed
  11. N/A Screening for Pregnancy Related Heart Failure in Nigeria Completed
  12. N/A Comparison of VF Induction Techniques During Medtronic ICD Implant (VF) (ICD) Completed
  13. N/A Cardio-pulmonary Rehabilitation and Sleep Quality Completed
  14. N/A BIOTRONIK Conduction System Pacing With the Solia Lead Completed
  15. N/A Same Day Subcutaneous ICD And Send Home (DASH) Completed
  16. N/A Physiologic Pacing Registry Completed
  17. N/A FAST (Fluid Accumulation Status Trial) Completed
  18. N/A Evaluating Myocardial Injury for Defibrillation Threshold Testing Methods for ICD Implantation Completed
  19. N/A Thoratec HeartMate II Left Ventricular Assist System (LVAS) for Bridge to Cardiac Transplantation Completed
  20. N/A InSync Model 8040 (InSync) and InSync III Model 8042 (InSync III) Registry Completed
  21. N/A Multicenter Automatic Defibrillator Implantation Trial - Chemotherapy-Induced Cardiomyopathy Completed
  22. N/A Assess Safety and Probable Benefit of the EXCOR® Pediatric Ventricular Assist Device Completed
  23. N/A Thoratec HeartMate II Left Ventricular Assist System (LVAS) for Destination Therapy Completed
  24. N/A RF Surgical Sponge-Detecting System on the Function of Pacemakers and Implantable Cardioverter Defibrillators Completed
  25. N/A Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease Completed
  26. N/A HIS-Purkinje Conduction System Pacing Optimized Trial of Cardiac Resynchronization Therapy Completed
  27. N/A Cardiomyopathy in DMD: Lisinopril vs. Losartan Completed
  28. N/A LBBAP Data Collection Registry Completed
  29. N/A Cardiac MRI for Metal on Metal Hip Resurfacing Completed
  30. N/A Adaptive CRT Effect on Electrical Dyssynchrony Completed

Showing the 36 most-cited and recently-updated of 36 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
MAPSE Predicts Adverse Events in Acute Myocarditis; Lateral MAPSE Shows Superior Performance
Cardiology Cohort
MAPSE Predicts Adverse Events in Acute Myocarditis; Lateral MAPSE Shows Superior Performance Could a simple heart measurement predict serious risks in myocarditis patients?
In a cohort of 46 acute myocarditis patients, reduced MAPSE was linked to major adverse cardiovascular events (MACE). Lateral MAPSE had a hi…
A simple heart measurement called MAPSE predicts serious risks and death in patients with acute myocarditis, helping doctors identify those …
Frontiers Mar 28, 2026

Questions about Cardiomyopathy

What causes sepsis-induced cardiomyopathy and what new treatments are available for it?

Sepsis-induced cardiomyopathy is caused by inflammation, mitochondrial damage, and calcium handling problems. New treatments include repurposed drugs, traditional Chinese medicine, and targeted therapies, but most need more testing.

Full answer →
Is the drug ifetroban safe for boys with Duchenne muscular disease and cardiomyopathy?

There is no confirmed safety data for ifetroban in boys with Duchenne muscular dystrophy and cardiomyopathy because the relevant Phase 2 trial has not yet published safety results.

Full answer →
Does having LGE-CMR positivity mean a higher risk of sudden death for cardiomyopathy patients?

Yes, LGE-CMR positivity is linked to a higher risk of sudden cardiac death in cardiomyopathy patients, especially those with non-ischemic cardiomyopathy.

Full answer →